Re: Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The
In Italy, AIFA has issued a decision to not reimburse VAZKEPA at this time. Another huge failure after Germany failed to agree on pricing too - Italy is a country that NEEDS V, and AMRN needed Italy! Now 2 of the EU big 5 have refused to pay for V - how many more years will AMRN just toddle along treading water? This is the kind of crap that is why nobody wants to BO AMRN - there's no meat on the bone, lousy adoption rate with a quickly approaching end to exclusivity.
